Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by qwerty22on Oct 22, 2021 1:45pm
170 Views
Post# 34038242

RE:RE:RE:RE:RE:New PR aroundVM

RE:RE:RE:RE:RE:New PR aroundVMMy last nerdy science comment (for now).

The two things I want to know going forward that isn't in this paper is

1) Whether they can really show some effect on exosome production as they might be hinting in the discussion.
2) What happens to SORT1 expression at the surface of the cell. One way the PDC might mimic SORT1 silencing would be to cause the SORT1 on the surface to get internalized and then stop it returning to the surface thus slowly depleting it. The PDCs might do that by shutting down the microtubule 'railways' that the endosome system runs on. In effect not just hijacking the endosome sytem to get inside the cell but also crippling the system. The exosomes run on the same railway and the signals that induce changes to the outside of the cell to cause migration and VM also have to run from the inside of the cell out. Seems like a neat way to bring these observations (and hints) together in a single mechanism (caveat : I don't really know what I'm talking about, just nerdy speculation)

If I was let lose in their labs I'd be hunting down ultracentrifuges to separate out exosomes on PDC-treated and untreated cells and perfecting my IHC skills to see if I could see changes in SORT1 expression levels at the cell surface following PDC treatment.


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse